+ 34 986 812 316

Cancer Epigenetics Group.
Institut d'Investigació Biomédica de Bellvitge (IDIBELL) Hospital Duran i Reynals 3a planta - Gran Via de l'Hospitalet, 199 08908 Hospitalet de Llobregat (Barcelona - Spain)

DNA methylation, non-coding RNAs, oncology, translational medicine, epigenetic therapy


cancer cell lines, mice models, patient samples


- Epigenetic profiling: Genome-wide characterization of CpG methylation (Illumina HiScanSQ technology); global analysis of methylcytosine content by HPLC-ESI/MS; ChIP on chip technology, MeDIP, analysis of histone marks in a cellular context (WB, ChiP, confocal microscopy,...), - Proteomic analysis. Quantitative proteomics (2D-DIGE, iTRAQ, SILAC) and Posttranslational modifications determination (CID and ETD fragmentation) - In vitro proliferation assays: MTT, colony formation assays, wound healing assay (in a panel of more than 150 cancer cell lines) - In vitro systems for genetic alterations: siRNA, genetic transfection - In vivo murine models (xenografts and patient derived xenografts),

Collaborations outside COST

We are in an institution devoted to translational research in biomedicine. In consequence, we reinforce collaboration with clinicians from National and International Medical Centers (mainly oncology but not restricted to). In previous FP7 and current H2020 projects, we also collaborate with experts in system biology and bioinfomaticians (analysis of *omics and algorithm’s development). Interaction with organic chemists is also frequent (epidrugs’s testing). Different SMEs help us with innovation and the technological transfer of our research.

Short description of ongoing research projects

Current research is aimed at the establishment of the epigenome maps of normal and transformed cells, the study of interactions between epigenetic modifications and non‐coding RNAs, and the development of new drugs for cancer. We are especially interested on the translational value of epigenetic research in oncology, so we are developing several projects together with private and public health services. Apart from oncology, we have specific projects in the area of: stem cell research, rare disorders associated with epigenetic defects (Sotos syndrome and Rett syndrome), metabolic diseases such as type-2 diabetes or neurological disorders (rare syndromes or Alzheimer disease).

  1. 1. Berdasco M, Esteller M (2013) Genetic syndromes caused by mutations in epigenetic genes. HUMAN GENETICS. 132(4):359-83
  2. 2. Barrero* MJ, Berdasco*M, Paramonov I, Bilic J, Vitaloni M, Esteller M, Belmonte JC (2012) DNA Hypermethylation in Somatic Cells Correlates with Higher Reprogramming Efficiency. STEM CELLS 30(8):1696-1702. * Equal contribution
  3. 3. Berdasco M, Esteller M (2010) Aberrant epigenetic landscape in cancer: how cellular identity goes awry. DEVELOPMENTAL CELL 19(5):698-711. Review.
  4. 4. Berdasco M, Ropero S, Setien F, Fraga MF, Lapunzina P, Losson R, Alaminos M, Cheung NK, Rahman N, Esteller M (2009) Epigenetic inactivation of the Sotos overgrowth syndrome gene histone methyltransferase NSD1 in human neuroblastoma and glioma. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE USA 106(51):21830-21835.
  5. 5. Teixeira FK, Heredia F, Sarazin A, Roudier F, Boccara M, Ciaudo C, Cruaud C, Poulain J, Berdasco M, Fraga MF, Voinnet O, Wincker P, Esteller M, Colot V (2009) A role for RNAi in the selective correction of DNA methylation defects. SCIENCE 323(5921):1600-1604.
Other activities of potential interest to others

• Associate Editor Clinical Epigenetics, • Member of the Ethics Committee of Bellvitge Hospital (evaluation of clinical trials). • Member of the Scientific Committee of Spanish National Association Against Cancer (AECC)

Cost UE